Ultra-fast semiconductor chipmakers have long awaited compounds that would increase chipset speed. To build a faster chipset, they needed a suitable material that exhibits higher charge mobility than silicon. Although several high-charge mobility compo …
To tolerate faults such as a single event upsets (SEUs) or single event transients (SETs), typical field programmable gate arrays (FPGAs) provide either fixed redundant circuitry or no redundancy at all, forcing users to program any required redundancy …
NASA’s Kennedy Space Center invites companies to license this innovative power-limiting circuit for batteries. This technology is designed to limit the power output from a battery without compromising battery lifetime in situations where there is littl …
Sense changes in shape in real time without affecting performance and without the need for structural modifications NASA’s Dryden Flight Research Center has developed a shape-sensing technology that offers high resolution (0.5-inch) at a 60-Hz r …
A simplified, cost-saving measurement device using optical transmission properties Innovators at NASA’s Marshall Space Flight Center have developed a unique prototype for measuring the liquid level in a tank, employing the properties of optical transmi …
Researchers at NASA’s Marshall Space Flight Center have developed and patented a low-cost, low-power method to monitor and detect gas leaks in vacuum or pressurized systems. The technology monitors for leaks of multiple types of gases up to ten million …
On October 29, 2003, Roche Diagnostics Corporation of Indianapolis, Ind. and Theron, Inc. of Carmel, Ind. signed an agreement that Theron would acquire licensing rights to Roche’s biosensor technology platform. With this technology, Theron will establish a new company to develop and sell products in the environmental and food safety testing markets. The events that led to the deal began the previous February, when Dr. Jörg Schreiber, Vice President of Special Products for Roche Diagnostics, approached Fuentek for assistance in determining the feasibility of out-licensing Roche’s flagship biosensor technology.
